Plaque Psoriasis

Thought leaders talk about blood monitoring protocols with deucravacitinib.

In this interview, Bhutani discussed a recent peer-reviewed study which highlighted concerns over skin cancer dangers for psoriasis patients treated with methotrexate.

The research method, which provides better context into patient and caregiver perspective on the field, has increased nearly two-fold in prevalence since 2020.

New research found that certain systemic markers in psoriatic arthritis and psoriasis patients correlated with PASI scores, indicating the clinical relevance of platelets and neutrophils in inflammation.

A retrospective analysis shows patients unresponsive to either secukinumab, ixekizumab or brodalumab may benefit from another of them.

This interview featured Mehmi discussing a less well-known form of melanoma known as mucosal melanoma, a condition which he believes needs to be researched in greater depth.

Findings from a Canadian routine care study showed that brodalumab was found to be effective for those with plaque psoriasis, with future real-world setting studies needed to learn more.

This study evaluated tranexamic acid injection for post-acne vulgaris erythema, though its smaller sample size may require the findings to be reproduced in large-scale studies.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, place the safety data for deucravacitinib in clinical context.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, explore the phase 3 data for deucravacitinib, as well as the dosage, and lack of drug-drug interactions associated with it.

Research indicates that despite reports of high psychological stress among women in their 20s and 30s in China and Japan, awareness of stress’s effects on aging remain higher among health professionals.

New data from a study in Italy found that, due to the lack of psoriasis drugs accounting for obesity, risankizumab was evaluated in patients with the inflammatory skin condition.

New results of the phase 3 ECZTRA 6 trial, evaluating tralokinumab for pediatric patients with eczema, found that the drug was superior to placebo in the primary and secondary endpoints.

New data indicates that there are significant bidirectional associations between migraines and psoriasis, with investigators recommending patients with either condition be informed about the connection.

It was announced by Arcutis Biotherapeutics that the US Food and Drug Administration had accepted for review their NDA for roflumilast foam 0.3%.

New study data re-evaluating current guidelines for T1a melanoma excisions indicate that 5-mm margins may be adequate in order to maintain lower risk levels for melanoma recurrence.

In another interview segment, a discussion was held with medical student Brenda Abreu Molnar about her experiences with epidermolysis bullosa patients and the SPD’s 2022 Medical Student Mentorship Award.

In this interview, medical student Brenda Abreu Molnar discussed the SPD’s 2022 Medical Student Mentorship Award and her experiences leading up to it.

Countries including Taiwan have observed a reduced frequency or resumption of in-person phototherapy for chronic skin conditions due to the pandemic.

New data indicates that there is a strong benefit-risk profile for upadacitinib for younger atopic dermatitis patients, with prior data predominantly relating to adult treatment.

Research was conducted on the paradoxical effect of TNF inhibitor–induced psoriasiform eruption in children and adolescents treated with inhibitors for conditions other than psoriasis.

A questionnaire analysis from Germany shows patients are more likely to be satisfied with the safety and convenience of their topical drugs than they are their effectiveness in treating psoriasis.

These findings indicate that managing obesity may be helpful in lessening the severity of atopic dermatitis for patients with both conditions.

New data suggests that patients with psoriasis may see positive outcomes after switching from secukinumab 150 mg to risankizumab 75 mg if secukinumab responses are inadequate.

In both the UK and Ireland, a new study found that there were increases in use of biosimilars to adalimumab and other tumor necrosis factor inhibitors for moderate-to-severe psoriasis.

New data from a study in Egypt suggests that several key factors contribute to some of the negative impacts of psoriasis on mothers of children with the skin condition.

A set of highlights from some of the impactful breakthroughs covered in dermatology this past month, including phase 3 trial data bimekizumab, tapinarof, and other treatments.

Thought leaders talk about the approval and integration of a first-in-class agent into the treatment armamentarium. They also review the mechanisms of TYK2 inhibition.

Linda Stein Gold, MD, and Bruce Strober, MD, PhD, assess the efficacy of traditional and newer treatment options for psoriasis. They also discuss therapeutic targets and the goals of therapy.

In another segment of her interview, Armstrong explained the implications of her team’s findings for the newly-developed TYK2 inhibitor for plaque psoriasis, as well as its safety profile data.